An interventional study of Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA in Pulmonary Embolism and Dyspnea, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by University Hospital, Brest · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Pulmonary Embolism by University Hospital, Brest — 5 open to participants now, 6 under way, none of them phase 3. Pulmonary Embolism · University Hospital, Brest.
Among the 20 studies in Pulmonary Embolism by University Hospital, Brest, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 10 with no phase, and was the 16th registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
Browse Pulmonary Embolism studies →5 of the 20 studies in Pulmonary Embolism by University Hospital, Brest are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Brest · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
University Hospital, Brest · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 32 is below the median of 174 across 429 interventional studies indexed under Pulmonary Embolism.
Median enrollment 374 across the 11 interventional studies, 374 across the 9 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Brest is the lead sponsor of 601 studies on the registry; 136 are open to participants now.
2 of the studies in Pulmonary Embolism by University Hospital, Brest that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05103670University Hospital, BrestVentilation/Perfusion PET/CT With Galligas and 68Ga-MAA for Regional Lung Function Assessment After Pulmonary Embolism | 2026-12-22 |
| NCT05015153University Hospital, BrestImpact on Quality of Life With Pulmonary RehAbilitation After Pulmonary eMBOlism: RAMBO Study | 2027-02-25 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Pulmonary Embolism by University Hospital, Brest, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In patients with pulmonary embolism (PE), after three or six months of anticoagulation, persistent dyspnea and impairment of quality of life are observed in at least 30% of cases.
The "RAMBO" trial is a French academic, multicenter, randomized (1:1 ratio), parallel arm, controlled, that aimed to assess the efficacy of pulmonary rehabilitation (PR) on the quality of life in patients with an acute symptomatic PE treated with anticoagulant therapy during at least 3 months and who present an impairment of quality of life and/or persistent dyspnea despite anticoagulant therapy.
Ventilation/Perfusion (V/Q) PET/CT is a novel imaging modality for the assessment of regional lung function. The same carrier molecules as conventional V/Q imaging are used, but they are labeled with 68Gallium, a ß+ isotope, instead of 99mTc, allowing acquisition of images with PET technology.
The EOLE study is an ancillary pilot study of the RAMBO trial, in which patients will benefit, in addition to the extensive work up scheduled as per study protocol, from a V/Q PET/CT scan before and after PR. The aim of the study is to assess the impact of PR on regional lung function with lung V/Q PET/CT imaging.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
After initial PR work up, patients with following criteria cannot be included:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EOLE is an ancillary study which selects patients included in the RAMBO study. The RAMBO study is a 2-arm-parallel study which patients included in one arm will undergo a 3-month pulmonary rehabilitation, and the patients included in the other arm won't. The EOLE study will include specific patients in both arms of the RAMBO study, and all of the participants will undergo a PET/CT scan at the inclusion and 3 months later.
Procedure: Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA
32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
Pulmonary vascular obstruction index (PVOI) on V/Q PET/CT imaging.
Expressed as a percentage of whole lung
Time frame: 3 months
Pulmonary ventilation impairment index on V/Q PET/CT imaging.
Expressed as a percentage of whole lung
Time frame: 3 months
Plan to share: Yes — All collected data that underlie results in a publication
Supporting information: Study protocol
Time frame: Data will be available beginning five years and ending fifteen years following the final study report completion
Access criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 125 non-industry interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 42 months is above that.
Counting every sponsor, half of 150 studies reached it within 25 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.